麗寶新藥生物科技
麗寶新藥成立於2017年01月，公司主旨專注於開發臨床市場未被滿足之需求(unmet need)的新型藥物。麗寶新藥營運模式採取聯合模組協同開發，將企業本體作為一個管理與核心技能(core competency)發展中心，藉由協調外部合作夥伴來進行快速的創新活動，並於營運時期的不同階段，採取『外部資源委託/合作執行模式』、『權利授權模式』、與『合作聯盟模式』，透過高度聯結來分散風險、活化資金流動、降低技術開發門檻。
- 成熟穩定期之新型藥物開發案
- 國際間腫瘤醫學合併療法(Combination Therapy)領域之投資熱點
- 以變動成本取代固定成本，增加資金運用的彈性
- 以授權引進、導出的活水式永續經營之商業模式，迅速創造可體現市值
- 國際策略聯盟體系
Business Model
Dr. Henry Liu is the co-founder and the CEO of Libo Pharma Corp., and shoulders the responsibility of leading, guiding, and overseeing the entire operation, growth and development of the company. Before appointed to be the CEO, Dr. Liu served as Vice President of Libo from 2017 to 2020.
Prior to leading the corporate spin-off of Libo Pharma Corp. from its parent company, Lihpao Life Sciences Corp. (LLSC) in 2017, Dr. Liu worked as an Executive Specialist for the General Manager at LLSC and assumed a wide variety of responsibilities: he directed and supervised several collaborative Next Generation Sequencing research projects in collaboration with clinical oncologists for developing companion diagnostics kits; established and managed international business relations and collaborations.
Dr. Liu received his BSc and MSc in Bioengineering from UC Berkeley and UC San Diego, respectively. He is also an active member of Taiwan Joint Commission of Precision Medicine.
– Henry Liu, Chief Executive Officer
Mandy M.-N. Lee co-founded Libo Pharma Corp. (Libo) with Dr. Henry Liu in 2017, and was named Director of Business Development & Licensing in 2019 . She is responsible for the company’s business development activities, including strategic planning, product portfolio and IP management, in/out-licensing evaluation, technology transfer oversight, and strategic alliance management .
Mandy M.-N. Lee earned her MSc. in Biological Sciences and Technology from National Chiao Tung University, where she is also a PhD candidate. In addition, she received intensive training in business and IP management from Foster school of Business executive education Multi-discipline management of technology program (University of Washington) , and the Europe IPRs programs in Munich (BOEHMERT & BOEHMERT law firm)
– Mandy Lee, Director of Business Development
Mr.Tsai has more than 13 years of experience in vaccine and biologic development and commercialization. Before taking on his current role, he spent 12 years at Merck Sharp and Dohme (MSD), serving in several research & development, technology, and manufacturing roles with increasing scope of responsibilities.
Mr.Tsai was Director of Global Vaccine Technical Operations at MSD from 2019-2021, during which he was responsible for the delivery of a brand-new vaccine commercial manufacturing asset and process. Prior to that, he led process development and commercialization teams supporting pipeline vaccine programs at MSD. He oversaw end-to-end programs starting from early/late-stage process development to commercial manufacturing and licensures (BLA/NDA).
Before joining the industry, Mr.Tsai obtained his Master Degree from University of Pennsylvania and a B.A degree from University of British Columbia.
– Peter Tsai, Head of Strategy & Alliance